secwatch.observer — SEC 8-K summary
======================================

Issuer:     F-star Therapeutics, Inc. (—)
CIK:        0001566373
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-065376
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

F-star Therapeutics acquired by invoX Pharma for $7.12 per share; merger completed
--------------------------------------------------------------------------------

- Tender offer expired with 16,308,869 shares (74.1%) tendered; all conditions met.
- Merger completed under Section 251(h); F-star becomes wholly owned subsidiary of invoX Pharma.
- Company shares to be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting.
- All directors and executive officers replaced; Eliot Forster and others departed; new board appointed.
- Aggregate merger consideration ~$119M; each share converted into $7.12 cash, net to holder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566373/000119312523065376/0001193125-23-065376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566373/000119312523065376/d398766d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-065376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer